Daniel Hughes

Daniel Hughes is a partner in the firm’s Business Law department and a member of its Technology and Life Sciences groups. Daniel advises clients on a wide range of matters, including start-up and formation, venture capital financings, mergers and acquisitions, initial public offering, capital markets transactions, private equity investments, and general corporate and securities law. He is also a Chartered Financial Analyst.

Prior to joining Goodwin, Daniel was an associate at another law firm in Boston.

Daniel’s recent representations include:

• Semma Therapeutics in its $950 million sale to Vertex
• FOG Pharmaceuticals in its $178 million Series D financing
• LifeMine Therapeutics in its $175 million Series C financing
• Gandeeva Therapeutics in its $40 million Series A financing
• Korro Bio in its $176 million Series B financing
• Navitor Pharmaceuticals in its acquisition of its subsidiary, Anakuria Therapeutics, to Janssen Pharmaceuticals
• Rodin Therapeutics in its $950 million acquisition by Alkermes
• CathWorks in its acquisition option agreement with Medtronic for up to $585 million upfront plus post-closing earn-out payments
• Monte Rosa Therapeutics in its $32.5 million Series A financing
• Monte Rosa Therapeutics in its $96 million Series B financing
• Monte Rosa Therapeutics in its $95 million Series C financing
• Monte Rosa Therapeutics in its $222.3 million initial public offering
• Cadent Therapeutics in its $770 million acquisition by Novartis
• Capstan Therapeutics in its $63 million Series Seed financing
• Capstan Therapeutics in its $102 million Series A financing
• Casma Therapeutics in its $50 million Series B financing
• Casma Therapeutics in its $46 million Series C financing
• 5AM Ventures as lead investor in a $45 million Series A financing and $60 million Series B financing of Neurogastrx
• Atlast Food Co. in its $40 million Series A financing
• Anelixis Therapeutics in its simultaneous sign and close “reverse” merger with Novus Therapeutics, and concurrent $108 million PIPE financing
• MBX Biosciences in its $35 million Series A financing
• MBX Biosciences in its $115 million Series B financing
• Axcella Health in its $60.1 million follow-on offering
• Axcella Health in its $35 million “at the market” offering
• Intellia Therapeutics in its expanded licensing agreement with Regeneron Pharmaceuticals
• Intellia Therapeutics in its acquisition of Rewrite Therapeutics
• Intellia Therapeutics in its $115 million secondary public offering
• Intellia Therapeutics in its $201 million secondary public offering
• Intellia Therapeutics in its $300 million secondary public offering
• Intellia Therapeutics in its $400 million “at-the-market” offering
• Intellia Therapeutics in its $600 million secondary public offering
• Navitor Pharmaceuticals in its development and option agreement with Supernus Pharmaceuticals
• Avadel Pharmaceuticals in its $65 million PIPE financing transaction
• The underwriters in Decibel Therapeutic’s $127 million initial public offering
• Aura Biosciences in its $80 million Series E financing
• Aura Biosciences in its $75.6 million initial public offering
• Aura Biosciences in its $75 million “at-the-market” offering
• Aura Biosciences in its $80.4 million secondary public offering
• Faze Medicines in its $81 million Series A financing
• Faze Medicines in its $81 million Series A financing

Daniel is a member of the CFA Society Boston and the Boston Bar Association.